These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32972198)

  • 41. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies.
    Srikantiah P; Vora P; Klugman KP
    Clin Infect Dis; 2021 Sep; 73(Suppl_3):S177-S179. PubMed ID: 34472571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
    Rossey I; Saelens X
    Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
    [No Abstract]   [Full Text] [Related]  

  • 43. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Global Respiratory Syncytial Virus-Related Infant Community Deaths.
    Mazur NI; Löwensteyn YN; Willemsen JE; Gill CJ; Forman L; Mwananyanda LM; Blau DM; Breiman RF; Madhi SA; Mahtab S; Gurley ES; El Arifeen S; Assefa N; Scott JAG; Onyango D; Tippet Barr BA; Kotloff KL; Sow SO; Mandomando I; Ogbuanu I; Jambai A; Bassat Q; ; Caballero MT; Polack FP; Omer S; Kazi AM; Simões EAF; Satav A; Bont LJ
    Clin Infect Dis; 2021 Sep; 73(Suppl_3):S229-S237. PubMed ID: 34472576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel therapies and vaccines against the human respiratory syncytial virus.
    Rivera CA; Gómez RS; Díaz RA; Céspedes PF; Espinoza JA; González PA; Riedel CA; Bueno SM; Kalergis AM
    Expert Opin Investig Drugs; 2015; 24(12):1613-30. PubMed ID: 26457559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Age-specific incidence rates and risk factors for respiratory syncytial virus-associated lower respiratory tract illness in cohort children under 5 years old in the Philippines.
    Ueno F; Tamaki R; Saito M; Okamoto M; Saito-Obata M; Kamigaki T; Suzuki A; Segubre-Mercado E; Aloyon HD; Tallo V; Lupisan SP; Oshitani H;
    Influenza Other Respir Viruses; 2019 Jul; 13(4):339-353. PubMed ID: 30891896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The point prevalence of respiratory syncytial virus in hospital and community-based studies in children from Northern Australia: studies in a 'high-risk' population.
    McCallum GB; Grimwood K; Oguoma VM; Leach AJ; Smith-Vaughan HC; Versteegh LA; Chang AB
    Rural Remote Health; 2019 Nov; 19(4):5267. PubMed ID: 31759384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Full compliance with Respiratory syncytial virus prophylaxis was associated with fewer respiratory-related hospital admissions in preterm children: A cohort study.
    Torchin H; Charkaluk ML; Rousseau J; Marchand-Martin L; Treluyer L; Nuytten A; Truffert P; Jarreau PH; Ancel PY
    Acta Paediatr; 2021 May; 110(5):1633-1638. PubMed ID: 33249609
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Respiratory syncytial virus: old challenges and new approaches.
    Chávez-Bueno S; Mejías A; Jafri HS; Ramilo O
    Pediatr Ann; 2005 Jan; 34(1):62-8. PubMed ID: 15693217
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The burgeoning burden of respiratory syncytial virus among children.
    Hall CB
    Infect Disord Drug Targets; 2012 Apr; 12(2):92-7. PubMed ID: 22335498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.
    Pan-Ngum W; Kinyanjui T; Kiti M; Taylor S; Toussaint JF; Saralamba S; Van Effelterre T; Nokes DJ; White LJ
    Vaccine; 2017 Jan; 35(2):403-409. PubMed ID: 27914740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A; Galvani AP; Meyers LA
    JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The future of respiratory syncytial virus vaccine development.
    Polack FP; Karron RA
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New drugs and treatment for respiratory syncytial virus.
    Maggon K; Barik S
    Rev Med Virol; 2004; 14(3):149-68. PubMed ID: 15124232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.